Nachrichten zur Eli Lilly & Co. Aktie

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) concluded the recent trading session at $905.03, signifying a -1.89% move from its prior days close.…

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust

And can Novo Nordisk catch up to its rival in the weight loss market?…

Lilly investing billions to prepare for overseas oral GLP-1 launches

With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40…

Top Stock Reports for Eli Lilly, Mastercard & AMD

Eli Lilly rides strong GLP-1 demand and pipeline momentum, while Mastercard and AMD navigate mixed performance and rising competition pressures.…

Leerink reiterates Eli Lilly stock rating on positive trial data

Leerink reiterates Eli Lilly stock rating on positive trial data…

Eli Lilly Isnt Replacing Zepbound -- Its Building an Obesity Empire

And its not too late to get in on the action.…

Hims And Hers Confronts Amazon Threat While Advancing AI Weight Loss Plan

Amazon Pharmacy has entered the weight loss medication market with Eli Lilly’s new GLP-1 drug, offering same day delivery and…

Eli Lilly: Warum Foundayo die Marktführerschaft im Adipositas-Sektor zementiert

Der Markt für Adipositas-Behandlungen erlebt derzeit eine fundamentale Verschiebung, und Eli Lilly positioniert sich mit der breiten Markteinführung seiner Abnehm-Pille…

Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India

Eli Lilly loses share in India’s GLP?1 market as cheap semaglutide generics surge, while Novo holds steady after deep price…

Amazon to stock Lillys new weight-loss pill at US kiosks, offer same-day delivery

Amazon.com said on Thursday its pharmacy unit will stock Eli Lillys new weight-loss pill at kiosks located at some of…

New weight-loss pill wins FDA approval as demand surges

Eli Lilly, the pharmaceutical giant, secured an important victory in the intensifying war against diabetes and obesity. Earlier this month,…

Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note

In the most recent trading session, Eli Lilly (LLY) closed at $953.3, indicating a +2.39% shift from the previous trading…

Is Eli Lilly Stock a Buy After a Brand New Approval?

The stocks dip might be an opportunity.…

Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines

Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI…

Eli Lillys One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

The U.S. Food & Drug Administration just approved Eli Lillys GLP-1 pill orforglipron.…

Eli Lilly (LLY) Stock Sinks As Market Gains: Heres Why

In the most recent trading session, Eli Lilly (LLY) closed at $935.58, indicating a -1.98% shift from the previous trading…

Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1

Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy…

Zulassung von Lillys Adipositas-Pille eröffnet neue Front im Abnehmkrieg

Die Pille des Pharmariesen wird auf dem boomenden, milliardenschweren Markt für Adipositas-Medikamente gegen einen Rivalen von Novo Nordisk antreten. Der…

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison

Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start…

Wall Street sees multi-billion dollar debut for Lillys obesity pill despite Novo lead

Eli Lillys newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts…

Novo VP Weighs In on Approval of Lilly’s Obesity Pill

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly’s once-daily weight-loss pill, called Foundayo, winning…

Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill

Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lillys obesity pill,…

AKTIE IM FOKUS: Eli Lilly ziehen weiter an - Diätpille in den USA zugelassen

NEW YORK (dpa-AFX) - Nach der Zulassung der Diätpille von Eli Lilly in den USA…

Eli Lilly opposes push to pass Trumps drug pricing deals into law, CEO says

Eli Lilly opposes the White Houses push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said…

Stocks making the biggest moves midday: Eli Lilly, Hasbro, Philip Morris, Intel, Micron & more

These are the stocks posting the largest moves in midday trading.…

FDA approves Eli Lillys GLP-1 pill, opening the next phase of the weight loss drug market

The FDA approval of Eli Lillys GLP-1 pill Foundayo comes nearly three months after Novo Nordisks oral version of Wegovy…

Lillys weight-loss pill wins US approval

The U.S. Food and Drug ?Administration on Wednesday approved Eli Lillys weight-loss pill, making it the second to market after…

Market movers: Nike, RH, Tiziana Life Sciences, Eli Lilly…

…

Eli Lilly weight loss pill Foundayo approved by FDA, shares rise

Eli Lilly and Co (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults…

Barclays reiterates Eli Lilly stock Overweight on acquisition

Barclays reiterates Eli Lilly stock Overweight on acquisition…

Heres Why Eli Lilly (LLY) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet

Eli Lilly said on Tuesday it would buy Centessa ?Pharmaceuticals ?in ?a deal valued at up to $7.8 billion.…

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly

Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and…

Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US

Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly ?prices…

Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash,…

Eli Lillys CEO Says This Could Be a Game Changer for Its Business

The healthcare stock may not be running out of growth catalysts anytime soon.…

Eli Lilly: 2,75-Mrd.-USD-Deal sichert KI-Wirkstoffe der nächsten Generation!

Eli Lilly baut sein Portfolio im Bereich der KI-gestützten Wirkstoffforschung durch eine bis zu 2,75 Mrd. USD schwere Vereinbarung mit…

Eli Lilly teams up with Insilico to accelerate AI-powered drug development

Eli Lilly and Co (NYSE:LLY) has entered into a drug discovery collaboration with Insilico Medicine, a clinical-stage biotechnology firm focused…

Prediction: Buying Pfizer Stock Today Could Set You Up for Life

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldnt count the company out.…

Healthcare ETFs in Spotlight Amid Eli Lilys $2.8B AI Drug Move

Eli Lillys $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven…

Eli Lilly expands AI drug push with multibillion-dollar Insilico deal

…

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the…

1 Reason Eli Lilly Stock Is Still a Buy

Eli Lilly is much more than just a weight loss stock.…

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Its not much of a contest right now.…

Could Buying Eli Lilly Today Set You Up for Life?

Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock.…

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

The latest trading day saw Eli Lilly (LLY) settling at $916.31, representing a +1.47% change from its previous close.…

Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.…

Top Analyst Reports for Eli Lilly, RTX & Abbott

Eli Lilly leads top analyst picks as GLP-1 demand, pipeline advances, and global growth momentum drive strong outlook despite rising…

U.S. executives, from Apple to Eli Lilly, revamp their push into the worlds second-largest economy at the China Development Forum

More than 80 global executives traveled to Beijing this weekend for the state-organized China Development Forum.…

Heres How Much Upside Eli Lilly Stock Has, According to Analysts

Eli Lillys stock has been receiving many upgrades after posting strong quarterly results in February.…